Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 04, 2010. The report serves as a notification to the market regarding the company's issued share capital and voting rights structure as of December 31, 2009, in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure data:
- Issued Share Capital: 5,665,128,359 Ordinary shares of 25p each.
- Treasury Shares: 474,194,158 Ordinary shares held in Treasury.
- Total Voting Rights: 5,190,934,201.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document presents a static snapshot of share capital as of the reporting date without comparative historical data.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification intended to assist shareholders in calculating disclosure thresholds under the Financial Services Authority's rules.
Investor Verification Checklist
- Verify the total number of voting rights (5,190,934,201) against current holdings to determine disclosure obligations.
- Confirm the number of shares held in Treasury (474,194,158) to understand the float available for trading.
- Review the company's Form 20-F for comprehensive financial performance data, as this 6-K contains only capital structure information.